Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

BACKGROUND: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order to identify additional biomarkers of cetuximab efficacy. METHODS: Previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Pentheroudakis, George, Kotoula, Vassiliki, De Roock, Wendy, Kouvatseas, George, Papakostas, Pavlos, Makatsoris, Thomas, Papamichael, Demetris, Xanthakis, Ioannis, Sgouros, Joseph, Televantou, Despina, Kafiri, Georgia, Tsamandas, Athanassios C, Razis, Evangelia, Galani, Eleni, Bafaloukos, Dimitrios, Efstratiou, Ioannis, Bompolaki, Iliada, Pectasides, Dimitrios, Pavlidis, Nicholas, Tejpar, Sabine, Fountzilas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599697/
https://www.ncbi.nlm.nih.gov/pubmed/23374602
http://dx.doi.org/10.1186/1471-2407-13-49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599697/
https://www.ncbi.nlm.nih.gov/pubmed/23374602
http://dx.doi.org/10.1186/1471-2407-13-49

Ejemplares similares